PropThink: PTN Succeeds In Key FSD Trial; Stock Has Room To Run

[ACN Newswire] – By David MoskowitzPalatin Technologies (AMEX:PTN) announced Thursday morning that its Phase IIb trial for bremelanotide met its primary endpoint, as well as secondary endpoints, for the treatment of female … more

View todays social media effects on PTN

View the latest stocks trending across Twitter. Click to view dashboard